Sunitinib is one of the standard targeted therapies used in metastatic renal cell carcinoma. It is generally a reasonably tolerated oral systemic therapy but can be occasionally associated with life-threatening toxicities. We present a case of reversible posterior encephalopathy, which is a rare but recognised side effect of the treatment.
JemalA., SiegelR., WardE., HaoY., XuJ., ThunM.J.: Cancer statistics, 2009.CA Cancer J Clin, 59: 225–249, 2009.
2.
MotzerR.J., MazumdarM., BacikJ., BergW., AmsterdamA., FerraraJ.: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.J Clin Oncol, 17: 2530–2540, 1999.
3.
MotzerR.J., MazumdarM., BacikJ., RussoP., BergW.J., MetzE.M.: Effect of cytokine therapy for survival for patients with advanced renal cell carcinoma.J Clin Oncol, 18: 1928–1935, 2000.
4.
RiniB.I., SosmanJ.A., MotzerR.J.: Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development.BJU Int, 96: 286–290, 2005.
5.
SulzbacherI., BirnerP., TraxlerM., MarbergerM., HaitelA.: Expression of platelet-derived growth factor-alpha alpha receptor is associated with tumor progression in clear cell renal carcinoma.Am J Clin Pathol, 120: 107–112, 2003.
6.
XuL., TongR., CochranD.M., JainR.K.: Blocking platelet-derived growth factor-D/platelet derived growth factor receptor beta signalling inhibits human renal cell carcinoma progression in an orthotopic mouse model.Cancer Res, 65: 5711–5719, 2005.
7.
O'FarrellA.M., AbramsT.J., YuenH.A., NgaiT.J., LouiseS.G., YeeK.W., WongL.M., HongW., LeeL.B., TownA., SmolichB.D., ManningW.C., MurrayL.J., HeinrichM.C., CherringtonJ.M.: SU 11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.Blood, 101: 3597–3605, 2003.
KwonE.J., KimS.W., KimK.K., SeoH.S., Kim doY.: A case of gemcitabine and cisplatin associated posterior reversible encephalopathy syndrome.Cancer Res Treat, 41: 53–55, 2009.
